Summary of YiFan Pharmaceutical Conference Call Company Overview - **Company**: YiFan Pharmaceutical - **Date**: August 15, 2025 Key Points Industry Performance - The domestic pharmaceutical market in the first half of 2025 showed a dichotomy, with traditional drug formulations under significant pressure while innovative drug companies exhibited notable growth potential [10][17]. Financial Performance - YiFan Pharmaceutical achieved revenue of **26.35 billion** yuan in the first half of 2025, showing slight growth compared to the previous year [3]. - Net profit increased by nearly **20%**, attributed to product structure transformation and high-margin products [3][16]. - Drug revenue accounted for approximately **80%** of total revenue, up from **40%** three years ago [16]. Product Performance - Key products in the first half of 2025 included: - **YiliShu**: Sales close to **500 million** yuan, with a target of **1 billion** yuan for the year [7]. - **Dinggan Cross-linked Sodium Hyaluronate**: Expected to double in sales volume [2]. - **Hiroda**: Revenue around **400 million** yuan, with a slight decline in price but stable gross margin due to production efficiency [9]. - **Children's Qingtiao**: Experienced a **30%-40%** decline due to demand and macroeconomic factors [8]. Innovation and R&D - Significant progress in innovative drug commercialization, with **YiliShu** achieving sales in over **40 countries** and receiving regulatory approval to shorten administration time in China [2][11]. - R&D investments increased, with the completion of Phase 1 clinical trials for a traditional Chinese medicine and advancements in several new drug projects [12][14]. Market Strategy - The company is implementing a differentiated pricing strategy globally, with the highest prices in the U.S. at **$4,600** per unit, followed by Europe and China [31][35]. - Plans to enter approximately **160 countries**, focusing on both high-price and competitive pricing markets [34][21]. Supply Chain and Production - The company optimized its international supply chain, transferring filling and packaging to FDA GMP-compliant facilities in China, significantly reducing production costs [4][28]. - Achieved EMA GMP and PIX certifications, enhancing product acceptance in international markets [13]. Future Outlook - The company anticipates stable growth in the second half of 2025, driven by increased sales of self-owned and innovative products [19][20]. - Long-term expectations for **YiliShu** and **Dinggan Cross-linked Sodium Hyaluronate** are optimistic, with significant market potential due to aging populations and clinical advantages [20][25]. Challenges and Opportunities - The company is aware of challenges posed by U.S.-China trade tensions but has strategies in place to mitigate risks, including adjusting transaction structures and leveraging potential tariff exemptions [38][46]. - The internationalization strategy includes expanding existing networks and exploring new markets, particularly in regions with high population but lower economic levels [39][45]. Conclusion - YiFan Pharmaceutical is positioned for growth through innovative products, strategic market expansion, and optimized operations, with a strong focus on R&D and international market penetration [14][47].

Core Insights - Chinese pharmaceutical companies are transitioning from "followers" to "leaders" in the global market, particularly focusing on Southeast Asia as a new growth area [1][3] - The recent secondary listing of Kangzhe Pharmaceutical on the Singapore Exchange marks a significant step in its internationalization strategy, aiming to leverage Southeast Asia's vast market potential [1][3][10] Market Expansion Strategies - Kangzhe Pharmaceutical is utilizing Singapore as a strategic hub to access the Southeast Asian pharmaceutical market, which has over 600 million people [3][10] - The company has established a comprehensive business ecosystem in Singapore, covering research, production, and sales, to enhance operational efficiency and market responsiveness [8][10][12] Challenges and Solutions - The company faces challenges such as fragmented regulations in emerging markets, varying payment capabilities, and differing healthcare needs across countries [5][6] - To address these challenges, Kangzhe Pharmaceutical has implemented localized registration strategies and established dedicated teams with extensive local experience [5][8] Product Focus and Innovation - Kangzhe Pharmaceutical is concentrating on specialized fields such as dermatology and ophthalmology, aiming to become a leader in niche markets rather than competing in saturated areas like oncology [13][14] - The company has a robust pipeline of approximately 40 innovative products, with a focus on high-quality, cost-effective solutions tailored to local market needs [14][17] Future Outlook - The company has invested over $100 million in the Southeast Asian and Middle Eastern markets over the past three years, indicating a strong commitment to expanding its footprint in these regions [10] - Kangzhe Pharmaceutical aims to leverage its established R&D capabilities and cost advantages from the Chinese market to enhance its product offerings in Southeast Asia [16][17]

Group 1: A-Share Market Overview - As of August 15, 2025, 505 A-share listed companies have disclosed their mid-year reports, with 106 companies showing private equity firms among their top ten circulating shareholders, collectively holding a market value of 25.164 billion yuan [1] Group 2: Hikvision (002415) Financial Performance - Hikvision reported a revenue of 41.818 billion yuan for the first half of 2025, representing a year-on-year growth of 1.48%, and a net profit attributable to shareholders of 5.657 billion yuan, up 11.71% year-on-year [2] - High Yi Asset has reduced its holdings in Hikvision, with its fund holding 338 million shares as of the end of Q2 2025, down by 12 million shares from the end of Q1 2025, resulting in a holding value of 9.373 billion yuan [2][3] Group 3: High Yi Asset's Investment Activities - High Yi Asset has continuously reduced its holdings in Hikvision for three consecutive quarters, totaling over 74 million shares since Q4 2024 [3] - In addition to Hikvision, High Yi Asset also reduced its stake in Dongcheng Pharmaceutical (002675), holding 17.5 million shares as of Q2 2025, down by 4 million shares, with a holding value of 252 million yuan [4] - High Yi Asset increased its holdings in Angel Yeast (600298) to 35 million shares by the end of Q2 2025, with a holding value of 1.231 billion yuan [4] Group 4: Other Private Equity Holdings - Freshwater Spring and Ying Shui Investment have disclosed their latest holdings, with Freshwater Spring holding 9.0333 million shares of Shengyi Technology (600183) valued at 272 million yuan, unchanged from Q1 2025 [5] - Ying Shui Investment holds shares in Yifan Pharmaceutical (002019), Sujiao Science (300284), and Hengwei Technology (603496), with a total of 24.67 million shares in Yifan Pharmaceutical valued at 321 million yuan, also unchanged from Q1 2025 [5] - Ying Shui Investment's funds are also present in Sujiao Science, holding 65.6691 million shares valued at 597 million yuan, with no change from Q1 2025 [5]

Core Viewpoint - The article highlights the recent disclosures of A-share listed companies' mid-year reports for 2025, revealing significant movements in private equity holdings, particularly the reduction of stakes by prominent private equity firms in companies like Hikvision and Dongcheng Pharmaceutical [1][2][3]. Group 1: A-share Listed Companies Mid-Year Reports - As of August 15, 2025, 505 A-share listed companies have disclosed their mid-year reports, with 106 companies showing private equity firms among their top ten shareholders, collectively holding a market value of 25.164 billion yuan [1]. - Hikvision reported a revenue of 41.818 billion yuan for the first half of 2025, reflecting a year-on-year growth of 1.48%, while net profit attributable to shareholders was 5.657 billion yuan, up 11.71% year-on-year [3]. Group 2: Hikvision Shareholding Changes - High Yi Asset has reduced its holdings in Hikvision, decreasing its shares by 12 million to 338 million, with a market value of 9.373 billion yuan as of the end of Q2 2025 [3][4]. - High Yi Asset has been consistently reducing its stake in Hikvision for three consecutive quarters, totaling over 74 million shares since Q4 2024 [4]. Group 3: Dongcheng Pharmaceutical Shareholding Changes - High Yi Asset also reduced its stake in Dongcheng Pharmaceutical, holding 17.5 million shares as of Q2 2025, down by 4 million shares, with a market value of 252 million yuan [5]. - The fund initially entered Dongcheng Pharmaceutical's top ten shareholders in Q2 2022 and had increased its holdings to 35 million shares before the recent reduction [5]. Group 4: Other Private Equity Movements - High Yi Asset increased its holdings in Angel Yeast, reaching 35 million shares with a market value of 1.231 billion yuan by the end of Q2 2025 [6]. - Other private equity firms, such as Danshuiquan and Ying Shui Investment, have also disclosed their major holdings, including investments in companies like Shengyi Technology and Yifan Pharmaceutical, with stable shareholding numbers compared to Q1 2025 [8][9].

Group 1 - The core viewpoint of the article is that Yifan Pharmaceutical expects to deliver over 450,000 units of Yilishu® throughout the year, with more than 40,000 units anticipated for the overseas market [1] - As of the first half of 2025, the company has already shipped over 220,000 units, indicating accelerated sales in the domestic terminal market [1] - The company plans to conduct a second shipment to its U.S. partner in the near future [1]

Core Insights - Yifan Pharmaceutical (002019) expects to ship over 450,000 units of Yilishu for the entire year, with more than 40,000 units anticipated for the overseas market [1] - As of the first half of 2025, the company has already shipped over 220,000 units externally, indicating accelerated sales growth in the domestic terminal market [1] - The company plans to make a second shipment to its U.S. partner in the near future [1]

Financial Performance - In the first half of 2025, the company achieved a revenue of 2.635 billion CNY, a slight increase compared to the same period last year [3] - The net profit attributable to shareholders reached 1.991 billion CNY, reflecting a growth of 3.04% year-on-year [3] - The non-deductible net profit was 2.37 billion CNY, marking a significant increase of 32.21% compared to the previous year [3] - The revenue from pharmaceutical-related sales accounted for 85.53% of total revenue, with overseas pharmaceutical formulations generating 332 million CNY, a growth of 6.46% year-on-year [3] Product Development and R&D Achievements - The company completed clinical trials for several innovative drugs and is advancing towards submitting IND applications for new projects [4] - The company has received registration certificates for two tumor products, enhancing its portfolio in the oncology sector [4] - The R&D efforts have transitioned into a positive cycle, with new products expected to drive future growth [4] Core Product: Yili Shu® - Yili Shu® achieved over 220,000 shipments in the first half of 2025, with a terminal price of 4,600 USD per unit in the U.S. market [5][9] - The product has established commercial partnerships in over 40 countries and regions, with approvals in 34 countries [8] - The company anticipates shipping over 450,000 units of Yili Shu® for the entire year, with over 40,000 units expected for overseas markets [9] Market Strategy and Pricing - The pricing strategy for Yili Shu® varies by region, with a premium price in the U.S. and competitive pricing in emerging markets [10] - The company aims to optimize its supply chain to reduce production costs and improve market access [6] - The global market for G-CSF products is estimated at approximately 22 million units, with Yili Shu® positioned to capture significant market share due to its clinical advantages [7] Core Product: Yini Kang® - Yini Kang® targets the growing market of osteoarthritis patients in China, with an estimated annual injection population of 3-5 million [11] - The product offers long-lasting effects and may delay functional deterioration, distinguishing it from short-acting alternatives [11] - The company is focused on building brand awareness and educating healthcare providers to enhance product adoption [12] International Business Expansion - The company has established a presence in over 50 countries, with production bases in Italy and a sales network across Southeast Asia [13][15] - The global BD center has facilitated partnerships with major pharmaceutical companies, enhancing the company's market reach [14] - The strategy includes both importing foreign products into China and exporting domestic innovations globally [14]

Core Viewpoint - Yifan Pharmaceutical (002019) reported a slight increase in total revenue and a significant rise in net profit for the first half of 2025, indicating improved profitability and operational efficiency [1]. Financial Performance - Total revenue for the first half of 2025 reached 2.635 billion yuan, a year-on-year increase of 0.11% [1]. - Net profit attributable to shareholders was 304 million yuan, up 19.91% year-on-year [1]. - In Q2 2025, total revenue was 1.308 billion yuan, reflecting a 0.18% increase year-on-year, while net profit for the quarter rose by 40.48% to 150 million yuan [1]. - Gross margin improved to 48.57%, an increase of 1.69% year-on-year, and net margin rose to 10.78%, up 33.6% year-on-year [1]. Cost Management - Total selling, administrative, and financial expenses amounted to 816 million yuan, accounting for 30.96% of revenue, a decrease of 3.47% year-on-year [1]. - The company reported a significant increase in operating cash flow per share, which reached 0.24 yuan, up 100.57% year-on-year [1]. Balance Sheet Changes - Construction in progress increased by 41.36% due to investments in various projects [3]. - Long-term borrowings rose by 19.13% due to changes in loan structure and new project financing [3]. - Accounts receivable increased by 7.069% to 1.541 billion yuan [1][3]. Cash Flow Analysis - Net cash flow from operating activities increased by 98.99%, driven by higher cash receipts from sales [4]. - Cash flow from financing activities decreased significantly by 170.94%, attributed to increased dividend payments and reduced financing from financial institutions [4]. Business Model and Market Position - The company's performance is primarily driven by research and marketing efforts, indicating a need for careful analysis of these underlying drivers [5]. - The core product, Yilishu, is expected to see significant sales growth, with projected net sales exceeding 500 million yuan in 2024 [8]. Investment Sentiment - The largest fund holding Yifan Pharmaceutical is the Caitong Asset Management Healthcare Mixed A fund, which recently increased its position [7]. - Analysts expect the company's performance in 2025 to reach 578 million yuan, with an average earnings per share of 0.47 yuan [6].

Core Insights - Yifan Pharmaceutical Co., Ltd. reported a slight increase in revenue and a significant rise in net profit for the first half of 2025, indicating a positive financial performance driven by its proprietary products and innovative drug commercialization efforts [1][2]. Financial Performance - The company achieved a revenue of 2.635 billion yuan, a year-on-year increase of 0.11% [1]. - Net profit attributable to shareholders reached 304 million yuan, reflecting a growth of 19.91% [1]. - The net profit excluding non-recurring items was 237 million yuan, up by 32.21% [1]. Business Segments - The proprietary pharmaceutical products segment, including imports, was the main driver of revenue growth, generating 1.990 billion yuan, a 7.22% increase [1]. - The innovative drugs, Yilishu® and Yinikang®, saw a combined sales revenue increase of 169.57%, significantly contributing to the rise in high-margin business and non-recurring profit margins [1][2]. Innovation and R&D - Yifan Pharmaceutical is one of the few Chinese companies approved for innovative biopharmaceuticals in multiple global markets, including China, the U.S., the EU, and Brazil [2]. - The company has a comprehensive lifecycle management system for new drug development, covering discovery, CMC research, clinical development, and commercial production [2]. - Ongoing projects include the exploration of multiple indications for F-652 and the completion of preclinical studies for the N-3C01 project, which is set to submit a clinical application soon [2]. Global Strategy - The company is enhancing its global strategy by merging its sales systems and establishing a global business division to streamline domestic and international sales [2]. - A global business development center has been created to strengthen external collaborations and resource integration, aiming to support stable revenue growth [3]. Market Position and Future Outlook - Yifan Pharmaceutical is recognized for its unique advantages in multi-indication development and global clinical design, despite some gaps compared to leading firms [2][3]. - The dual focus on technological R&D and market expansion is creating a "flywheel effect," enhancing profitability and supporting global market expansion [3].

Group 1 - Baiya Co., Ltd. achieved a net profit of 188 million yuan in the first half of 2025, a year-on-year increase of 4.64% [1] - The company reported an operating income of 1.764 billion yuan, up 15.12% year-on-year [1] - Basic earnings per share were 0.44 yuan [1] Group 2 - Leike Defense reported a net loss of 41.67 million yuan in the first half of 2025, compared to a loss of 66.43 million yuan in the same period last year [2] - The company achieved an operating income of 542 million yuan, a year-on-year increase of 9.77% [2] - Basic earnings per share were -0.03 yuan [2] Group 3 - Jinggong Technology achieved a net profit of 113 million yuan in the first half of 2025, a year-on-year increase of 15.55% [3] - The company reported an operating income of 1.061 billion yuan, up 10.31% year-on-year [3] - Basic earnings per share were 0.22 yuan [3] Group 4 - Yuejian Intelligent reported a net profit of 62.63 million yuan in the first half of 2025, a year-on-year increase of 46.99% [4] - The company achieved an operating income of 651 million yuan, up 13.22% year-on-year [4] - Basic earnings per share were 0.2436 yuan [4] Group 5 - Wanwei High-tech achieved a net profit of 256 million yuan in the first half of 2025, a year-on-year increase of 97.47% [6] - The company reported an operating income of 4.061 billion yuan, up 4.90% year-on-year [6] - Basic earnings per share were 0.122 yuan [6] Group 6 - Keli Equipment achieved a net profit of 82.78 million yuan in the first half of 2025, a year-on-year increase of 4.88% [7] - The company reported an operating income of 318 million yuan, up 12.41% year-on-year [7] - Basic earnings per share were 0.87 yuan [7] Group 7 - Jinwo Co., Ltd. achieved a net profit of 25.47 million yuan in the first half of 2025, a year-on-year increase of 94% [8] - The company reported an operating income of 614 million yuan, up 7.96% year-on-year [8] - Basic earnings per share were 0.21 yuan [8] Group 8 - Longyuan Technology achieved a net profit of 28.28 million yuan in the first half of 2025, a year-on-year increase of 135.6% [10] - The company reported an operating income of 362 million yuan, up 1.48% year-on-year [10] - Basic earnings per share were 0.0548 yuan [10] Group 9 - Guangting Information achieved a net profit of 42.92 million yuan in the first half of 2025, turning from loss to profit [13] - The company reported an operating income of 275 million yuan, up 26.88% year-on-year [13] - Basic earnings per share were 0.4633 yuan [13] Group 10 - Changjiang Materials achieved a net profit of 73.38 million yuan in the first half of 2025, a year-on-year increase of 5.03% [15] - The company reported an operating income of 513 million yuan, up 10.43% year-on-year [15] - Basic earnings per share were 0.5019 yuan [15] Group 11 - Yitong Century reported a net loss of 1.77 million yuan in the first half of 2025, compared to a profit of 35.87 million yuan in the same period last year [17] - The company achieved an operating income of 1.22 billion yuan, down 0.54% year-on-year [17] - Basic earnings per share were -0.0020 yuan [17] Group 12 - China Nuclear Construction signed new contracts worth 90.48 billion yuan in July 2025 [19] - The company achieved a cumulative operating income of 58.229 billion yuan [19] Group 13 - Yinlong Co., Ltd. signed a construction labor subcontracting contract worth 108 million yuan [21] - The contract is for the prefabrication of CRTSIII-type track slabs for a railway project [21] Group 14 - Xinan Century plans to apply for a comprehensive credit limit of no more than 50 million yuan from a bank [23] - The limit will be used for various business purposes including working capital loans [23] Group 15 - New Hongtai reported a net profit of 34.27 million yuan in the first half of 2025, a year-on-year decrease of 8.94% [25] - The company achieved an operating income of 308 million yuan, down 2.45% year-on-year [25] - Basic earnings per share were 0.23 yuan [25] Group 16 - Botong Co., Ltd. achieved a net profit of 13.33 million yuan in the first half of 2025, a year-on-year increase of 42.95% [26] - The company reported an operating income of 149 million yuan, up 5.23% year-on-year [26] - Basic earnings per share were 0.2135 yuan [26] Group 17 - Minfeng Special Paper reported a net profit of 15.07 million yuan in the first half of 2025, a year-on-year decrease of 68.88% [28] - The company achieved an operating income of 601 million yuan, down 23.21% year-on-year [28] - Basic earnings per share were 0.043 yuan [28] Group 18 - Changchun Yidong announced that a shareholder plans to reduce their stake by up to 2.97% [29] - The reduction period is from September 8, 2025, to December 5, 2025 [29] Group 19 - Jiukang Bio received an invention patent certificate for a reagent [30] - The patent involves the application of a specific enzyme in diagnostic reagents [30] Group 20 - Xuelang Environment announced the resignation of its general manager due to personal reasons [31] - The chairman will temporarily take over the general manager's responsibilities [31] Group 21 - Tailin Bio's subsidiary obtained a property certificate for industrial land [32] - The land area is 20,500 square meters with a usage period until July 6, 2075 [32] Group 22 - Changgao Electric New's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [33] Group 23 - Tianyoude Wine plans to use up to 147 million yuan of idle funds for cash management [34] Group 24 - Lingxiao Pump Industry used 5.9 million yuan of idle funds to purchase financial products [36] Group 25 - Mengke Pharmaceutical announced that a shareholder plans to reduce their stake by up to 3% [38] Group 26 - Kexiang Co., Ltd. plans to raise no more than 300 million yuan through a simplified procedure [40] Group 27 - Huagong Technology achieved a net profit of 911 million yuan in the first half of 2025, a year-on-year increase of 44.87% [42] - The company reported an operating income of 7.629 billion yuan, up 44.66% year-on-year [42] - Basic earnings per share were 0.91 yuan [42] Group 28 - Shanghai Jianke achieved a net profit of 23.76 million yuan in the first half of 2025, a year-on-year increase of 48.57% [43] - The company reported an operating income of 1.935 billion yuan, up 0.60% year-on-year [43] - Basic earnings per share were 0.06 yuan [43] Group 29 - Darui Electronics achieved a net profit of 132 million yuan in the first half of 2025, a year-on-year increase of 25.32% [44] - The company reported an operating income of 1.405 billion yuan, up 28.04% year-on-year [44] - Basic earnings per share were 1.00 yuan [44] Group 30 - Dongyangguang achieved a net profit of 613 million yuan in the first half of 2025, a year-on-year increase of 170.57% [45] - The company reported an operating income of 7.124 billion yuan, up 18.48% year-on-year [45] - Basic earnings per share were 0.209 yuan [45] Group 31 - Chongqing Beer reported a net profit of 865 million yuan in the first half of 2025, a year-on-year decrease of 4.03% [49] - The company achieved an operating income of 8.839 billion yuan, down 0.24% year-on-year [49] - Basic earnings per share were 1.79 yuan [49] Group 32 - Chongqing Beer announced that its subsidiary plans to increase capital by 600 million yuan [51] Group 33 - Meixin Technology announced that a shareholder plans to reduce their stake by up to 3% [53] Group 34 - Qipai Technology plans to raise no more than 159 million yuan through a private placement [55] Group 35 - Qipai Technology reported a net loss of 586.69 million yuan in the first half of 2025 [57] - The company achieved an operating income of 326 million yuan, up 4.09% year-on-year [57] - Basic earnings per share were -0.55 yuan [57] Group 36 - Huaying Technology reported a net loss of 476 million yuan in the first half of 2025 [59] - The company achieved an operating income of 721 million yuan, down 16.59% year-on-year [59] - Basic earnings per share were -0.1723 yuan [59] Group 37 - Best reported a net profit of 148 million yuan in the first half of 2025, a year-on-year increase of 3.30% [61] - The company achieved an operating income of 716 million yuan, up 2.73% year-on-year [61] - Basic earnings per share were 0.2966 yuan [61] Group 38 - Changliang Technology reported a net loss of 19.11 million yuan in the first half of 2025 [62] - The company achieved an operating income of 664 million yuan, down 5.64% year-on-year [62] - Basic earnings per share were -0.0236 yuan [62] Group 39 - Shunhao Co., Ltd. plans to use up to 35 million yuan of idle funds for entrusted wealth management [64] Group 40 - Weihede achieved a net profit of 65.97 million yuan in the first half of 2025, a year-on-year increase of 24.69% [66] - The company reported an operating income of 356 million yuan, up 38.37% year-on-year [66] - Basic earnings per share were 0.49 yuan [66] Group 41 - Huafa Co., Ltd. reported a net profit of 172 million yuan in the first half of 2025, a year-on-year decrease of 86.41% [67] - The company achieved an operating income of 38.199 billion yuan, up 53.46% year-on-year [67] - Basic earnings per share were 0.06 yuan [67] Group 42 - Mankun Technology achieved a net profit of 632 million yuan in the first half of 2025, a year-on-year increase of 62.30% [68] - The company reported an operating income of 760 million yuan, up 31.56% year-on-year [68] - Basic earnings per share were 0.43 yuan [68] Group 43 - Kelu Electronics achieved a net profit of 190 million yuan in the first half of 2025, turning from loss to profit [69] - The company reported an operating income of 2.573 billion yuan, up 34.66% year-on-year [69] - Basic earnings per share were 0.1144 yuan [69] Group 44 - Sanrenxing achieved a net profit of 144 million yuan in the first half of 2025, a year-on-year increase of 10.83% [71] - The company reported an operating income of 1.657 billion yuan, down 13.36% year-on-year [71] - Basic earnings per share were 0.68 yuan [71] Group 45 - Xinwei Communication achieved a net profit of 162 million yuan in the first half of 2025, a year-on-year decrease of 20.18% [72] - The company reported an operating income of 3.703 billion yuan, down 1.15% year-on-year [72] - Basic earnings per share were 0.1699 yuan [72] Group 46 - Yifan Pharmaceutical achieved a net profit of 304 million yuan in the first half of 2025, a year-on-year increase of 19.91% [72] - The company reported an operating income of 2.635 billion yuan, up 0.11% year-on-year [72] - Basic earnings per share were 0.25 yuan [72] Group 47 - *ST Chengchang achieved a net profit of 566 million yuan in the first half of 2025, turning from loss to profit [73] - The company reported an operating income of 201 million yuan, up 180.16% year-on-year [73] - Basic earnings per share were 0.2783 yuan [73] Group 48 - Rejing Bio announced that a controlling shareholder plans to reduce their stake by up to 1.08% [74] Group 49 - Jingu Co., Ltd. signed a strategic cooperation framework agreement with Luming Robotics [75]